Moreover, many approaches have developed TLR4 antagonists such as TAK-242 (CLI-095), which have advanced to block TLR4 signaling in various diseases such as sepsis, septic shock, rheumatoid arthritis, and lung inflammation [8]. This evidence concerns the gene TLR4 and rheumatoid arthritis.